Skip to main content
OpenTrials
Completed

NCT Number: NCT02575625

Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis

Hypothesis of this study is the existence of a relation between parameters measured by FibroScan® FS 502 according to our non invasive method and liver steatosis condition.

This proof of concept validation is made up of two steps:

* Step 1: feasibility study of the method on 10 healthy volunteers * Step 2: diagnosis study on 50 healthy volunteers (25 between 18-30 years-old and 25 between 40-65 years-old) and on 25 patients whom cares including an liver biopsy et whom the histological answer is clean steatosis (NAFLD).

Experimental procedures consist in:

* Fibroscan measure, preceded by tracking ultrasonography. * liver MRI (for substudy about MRI comparison, in step 2) * a blood test for biological assessment of liver functions

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital of Tours

Tours, 37044, France

About this study

Diagnosis of liver lipid overload (named liver steatosis), unrelated to alcohol consumption, still mainly based on histological exam of the liver. An histological continuity exists going from clean liver steatosis (Non Alcoholic Fatty Liver Disease, NAFLD) to steatohepatitis with signs of inflammation and tissue fibrosis (Non Alcoholic Steato-Hepatitis, NASH). It's now well-known that disease can evolve to cirrhosis and its complications.

Hypothesis of this study is the existence of a relation between parameters measured by FibroScan® FS 502 according to our non invasive method and liver steatosis condition.

This proof of concept validation is made up of two steps:

  • Step 1: feasibility study of the method on 10 healthy volunteers
  • Step 2: diagnosis study on 50 healthy volunteers (25 between 18-30 years-old and 25 between 40-65 years-old) and on 25 patients whom cares including an liver biopsy et whom the histological answer is clean steatosis (NAFLD).

Measures on healthy volunteers enable to do an intra-operator reproductibility analysis, a study of an age effect and a search of potential mechanic aging of the liver.

Experimental procedures consist in:

  • Fibroscan measure, preceded by tracking ultrasonography.
  • liver MRI (for substudy about MRI comparison, in step 2)
  • a blood test for biological assessment of liver functions

The final aim of this study is to propose a device enable medical community to do in vivo hepatic rheology observation, highly correlated to liver lipid overload. After industrialization of this innovation, this diffusion could making easier patients follow-up.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy subjects - Steps 1 and 2
  • Age between 18 and 65 years old (2 age groups for step 2 : 18-30 et 40-65 years-old)
  • Written inform consent form signed
  • Affiliated to medical insurance
  • Alcohol consumption d'alcool < 20g/j for women, <30g/j for men
  • Patients with liver steatosis - Step 2
  • More than 18 years -old
  • Written inform consent form signed
  • Affiliated to medical insurance
  • Patients with clean steatosis confirmed by histological results of a liver biopsy done the previous month
  • Alcohol consumption d'alcool < 20g/j for women, <30g/j for men

Exclusion criteria

  • Healthy subjects - Step 1
  • Exposure to chemical poisons (solvents, paints, drugs) in the previous 4 weeks
  • Pregnant women, lactating women, and women in age for procreation and without reliable contraception
  • Presence of ascites
  • Person under guardianship
  • Healthy subjects - Step 2
  • Exposure to chemical poisons (solvents, paints, drugs) in the previous 4 weeks
  • Pregnant women, lactating women, and women in age for procreation and without reliable contraception
  • Contraindication to MRI
  • Presence of ascites
  • Person under guardianship
  • Healthy subjects - Steps 1 and 2
  • Presence of liver tumor or ascites (diagnosed with MRI or ultrasonography)
  • Abnormal liver function tests (increase of transaminases, gammaGT)
  • Patients with liver steatosis - Step 2
  • Exposure to chemical poisons (solvents, paints, drugs) in the previous 4 weeks
  • Pregnant women, lactating women, and women in age for procreation and without reliable contraception
  • Contraindication to MRI
  • Presence of ascites
  • liver tumor
  • Serology anti VHC+ or Ag HBs+
  • Infection by HIV
  • Auto-immun hepatitis
  • Genetic hemochromatosis, Wilson disease, lake of alpha-1-antitrypsin
  • Fibrosis or liver cirrhosis at biopsy
  • Person under guardianship

Treatment and study plan

FibroScan

Device

Three series oh independent measures Measure done with Fibroscan will be preceded by tracking ultrasonography.

Blood test for biological assessment of liver function

Biological

Blood test for biological assessment of liver function

MRI

Device

Liver MRI

Primary outcomes

  1. Viscosity in Pa.s

    Time frame: One day

    Digital files recorded by medical device will be mathematically processed for extracting elasticity G' and viscosity G'' curves in accordance with the frequency. These curves use to identify the 5 parameters: mu(M), eta(M), alpha, mu(V), eta(V); which describe visco-elasticity variations with frequency thanks to an Matlab algorithm

  2. Elasticity in kPa

    Time frame: One day

    Digital files recorded by medical device will be mathematically processed for extracting elasticity G' and viscosity G'' curves in accordance with the frequency. These curves use to identify the 5 parameters: mu(M), eta(M), alpha, mu(V), eta(V); which describe visco-elasticity variations with frequency thanks to an Matlab algorithm

Secondary outcomes

  1. Reproductibility quantification in arbitrary unit

    Time frame: through study completion, an average of 2 years

    The 5 estimated parameters (which describe visco-elasticity) will be used to quantify the medical device reproductibility

  2. Age in years

    Time frame: through study completion, an average of 2 years

    The 5 estimated parameters (which describe visco-elasticity) and the age oh the healthy volunteers wil be used to study an age effect

  3. Liver signal intensity changes in decibel

    Time frame: through study completion, an average of 2 years

    Adiposis charge will be assessed by measure of liver signal intensity decrease on T1 sequence in phase opposition compared to in phase signal, after correction by iron quantity

Sponsors and collaborators

Lead sponsor

University Hospital, Tours

Other

Collaborators

  • Echosens
  • Institut National de la Santé Et de la Recherche Médicale, France

Registry information

Acronym: TRANSTEATOSE

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Oct 14, 2015
Registry last updated
Jun 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.